Acadian Asset Management LLC Raises Position in Gossamer Bio, Inc. $GOSS

Acadian Asset Management LLC lifted its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 12.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,146,022 shares of the company’s stock after buying an additional 787,909 shares during the period. Acadian Asset Management LLC owned about 3.14% of Gossamer Bio worth $8,786,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in Gossamer Bio by 107.2% in the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after acquiring an additional 43,866 shares during the last quarter. Mackenzie Financial Corp increased its holdings in shares of Gossamer Bio by 17.6% in the 1st quarter. Mackenzie Financial Corp now owns 352,473 shares of the company’s stock worth $388,000 after purchasing an additional 52,658 shares in the last quarter. Invesco Ltd. purchased a new position in shares of Gossamer Bio in the first quarter worth $48,000. Virtu Financial LLC bought a new position in shares of Gossamer Bio during the first quarter valued at $38,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Gossamer Bio during the first quarter valued at $387,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on GOSS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Wedbush lifted their price target on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a research report on Thursday, September 11th. Finally, Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $2.70 on Thursday. Gossamer Bio, Inc. has a one year low of $0.66 and a one year high of $3.60. The business has a fifty day moving average price of $2.62 and a 200-day moving average price of $1.91. The firm has a market capitalization of $624.94 million, a price-to-earnings ratio of -3.91 and a beta of 1.85.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $13.29 million for the quarter, compared to the consensus estimate of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. On average, equities research analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.